Search Result

Pathways Recommended:	Stem Cell/Wnt Neuronal Signaling JAK/STAT Signaling

Results for "

Wnt/β-Catenin signaling

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Wnt (71) β-catenin (62) Antibiotic (5) Apoptosis (12) Autophagy (7) Bacterial (4) Bcl-2 Family (1) c-Myc (1) Carbonic Anhydrase (1) Casein Kinase (2) CDK (6) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) ERK (3) Estrogen Receptor/ERR (1) Glucocorticoid Receptor (2) GSK-3 (8) Histone Acetyltransferase (1) Histone Demethylase (1) HSP (1) JNK (1) Mitophagy (1) MMP (3) Neuropeptide Y Receptor (1) NF-κB (3) NOD-like Receptor (NLR) (1) Organoid (5) P-glycoprotein (1) p38 MAPK (2) Parasite (3) PARP (2) Phosphodiesterase (PDE) (2) Porcupine (1) PROTACs (3) Pyroptosis (1) RANKL/RANK (4) Reactive Oxygen Species (2) Sodium Channel (1) STAT (2) Survivin (1) Toll-like Receptor (TLR) (4)
By Research Areas:	Cancer (72) Cardiovascular Disease (5) Endocrinology (2) Infection (3) Inflammation/Immunology (16) Metabolic Disease (17) Neurological Disease (12)

By Targets:

Wnt (71)

β-catenin (62)

Antibiotic (5)

Apoptosis (12)

Autophagy (7)

Bacterial (4)

Bcl-2 Family (1)

c-Myc (1)

Carbonic Anhydrase (1)

Casein Kinase (2)

CDK (6)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (1)

ERK (3)

Estrogen Receptor/ERR (1)

Glucocorticoid Receptor (2)

GSK-3 (8)

Histone Acetyltransferase (1)

Histone Demethylase (1)

HSP (1)

JNK (1)

Mitophagy (1)

MMP (3)

Neuropeptide Y Receptor (1)

NF-κB (3)

NOD-like Receptor (NLR) (1)

Organoid (5)

P-glycoprotein (1)

p38 MAPK (2)

Parasite (3)

PARP (2)

Phosphodiesterase (PDE) (2)

Porcupine (1)

PROTACs (3)

Pyroptosis (1)

RANKL/RANK (4)

Reactive Oxygen Species (2)

Sodium Channel (1)

STAT (2)

Survivin (1)

Toll-like Receptor (TLR) (4)

By Research Areas:

Cancer (72)

Cardiovascular Disease (5)

Endocrinology (2)

Infection (3)

Inflammation/Immunology (16)

Metabolic Disease (17)

Neurological Disease (12)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: Wnt β-catenin RGS Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18959

CWP232228 5 Publications Verification	β-catenin Wnt	Cancer
CWP232228, a highly potent selective *Wnt/β-catenin* signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .

HY-115543

β-catenin-IN-37	β-catenin	Cancer
β-catenin-IN-37 is a selective β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively .

HY-115539

Windorphen	Wnt β-catenin Histone Acetyltransferase	Cancer
Windorphen is a *Wnt/β-catenin* signal inhibitor that specifically targets the function of the c-terminal transactivation domain of *β-catenin-1* but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP .

HY-120697

MSAB 20+ Cited Publications	Wnt β-catenin	Cancer
MSAB is a potent and selective inhibitor of *Wnt/β-catenin* signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells .

HY-121118

Coronaridine 1 Publications Verification	Wnt	Neurological Disease Cancer
Coronaridine, an iboga type alkaloid, inhibits the **wnt signaling** pathway by decreasing β-catenin expression .

HY-P5819

xStAx-VHLL	Wnt PROTACs β-catenin	Cancer
xStAx-VHLL is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of *β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin* signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin Wnt	Cancer
xStAx-VHLL TFA is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of *β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin* signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-160489

PTK7/β-catenin-IN-2	β-catenin	Cancer
PTK7/β-catenin-IN-2 (compound 04967) is an inhibitor of *PTK7/β-catenin*. It inhibits the binding of PTK7 to β-catenin (IC₅₀: 5.6 μM), thereby inhibiting the signaling of the Wnt/β-catenin pathway. PTK7/β-catenin-IN-2 targets cell growth dependent on the Wnt signaling pathway and has anticancer properties. PTK7/β-catenin-IN-2 also showed inhibitory potency against p53 and MDM2 binding with an IC₅₀ of 157.1 μM .

HY-169126

β-catenin modulator IIa-661	β-catenin Wnt	Cancer
β-catenin modulator IIa-661 is a *β-catenin* modulator that modulates β-catenin activity and inhibits the activity of the Wnt/wingless (wg) signaling pathway. β-catenin modulator IIa-661 can be utilized in cancer research .

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-164520

PMED-1	Wnt	Cancer
PMED-1 is a *β-catenin* inhibitor that significantly reduces *β-catenin* activity in hepatoblastoma cells and various HCC cells, with an IC₅₀ value ranging from 4.87 to 32 μM. PMED-1 affects *Wnt* signaling by decreasing the interaction between *β-catenin* and CREB binding protein, thereby inhibiting cell proliferation. PMED-1 has potential applications in cancer research .

HY-160493

PTK7/β-catenin-IN-6	Wnt β-catenin	Cancer
PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .

HY-13815

KY02111 5 Publications Verification	Wnt	Cardiovascular Disease
KY02111 is a canonical **WNT signaling (β-catenin)** inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .

HY-112799

DK419	Wnt β-catenin	Cancer
DK419 is a potent and orally active *Wnt/β-catenin* signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .

HY-151520

Wnt/β-catenin agonist 4	Wnt	Cancer
Wnt/β-catenin agonist 4 (Derivative 83) is an agonist of *Wnt* that activates *Wnt/β-catenin* signal transmission .

HY-141873

Wnt/β-catenin agonist 2	β-catenin	Others
Wnt/β-catenin agonist 2 is a potent *Wnt* agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction . (From patent WO2007078113A1, compound 39)

HY-163409

CGK012	β-catenin	Inflammation/Immunology Cancer
CKG012 is an inhibitor for *Wnt/βcatenin* signaling pathway. CGK012 inhibits release of HMGB1 and transcription of β-catenin, exhibits attenuating activities against cecal ligation and puncture (CLP)-induced sepsis and multiple myeloma cancer .

HY-141543

YW2065	β-catenin	Cancer
YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of *β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of *wnt/β-catenin signaling inhibition and AMPK** activation .

HY-148055

Wnt/β-catenin agonist 3	β-catenin	Cardiovascular Disease
Wnt/β-catenin agonist 3 (compound 98) is a *Wnt/β-catenin* signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis .

HY-148055A

Wnt/β-catenin agonist 3 hydrochloride	β-catenin	Others
Wnt/β-catenin agonist 3 hydrochloride is a *Wnt/β-catenin* signalling pathway agonist. Wnt/β-catenin agonist 3 (compound 98) can be used for the research of osteoporosis .

HY-133180

YW1128	Wnt β-catenin	Metabolic Disease
YW1128 (compound 3a) is a potent *Wnt/β-Catenin* inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .

HY-108442

JW67 1 Publications Verification	Wnt	Cancer
JW67 inhibits the canonical *Wnt* signaling with an IC₅₀ of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of *Wnt* target genes. JW67 also inhibits colorectal cancer cell growth .

HY-114321

Wnt/β-catenin agonist 1 4 Publications Verification	Wnt	Cancer
Wnt/β-catenin agonist 1 (compound 3f) is a *Wnt/β-catenin* signalling pathway agonist, with an EC₅₀ of 0.27 μM .

HY-160709

Wnt/β-catenin-IN-2	Wnt β-catenin	Cancer
Wnt/β-catenin-IN-2 (Compound 3235-0367) is a *Wnt/β-catenin* signaling pathway inhibitor, with IC₅₀ and K_D values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer .

HY-138301

Miclxin DS37262926	β-catenin	Cancer
Miclxin (DS37262926) is a potent inhibitor of mutant *β-catenin, involving in Wnt* signaling pathway. Miclxin induces β-catenin-dependent apoptosis, leads to severe mitochondrial damage with the loss of mitochondrial membrane. Miclxin kills tumor via targeting to MIC60, a major components of the mitochondrial contact site and cristae organizing system (MICOS) complex .

HY-157990

Wnt/β-catenin-IN-1	Wnt β-catenin	Cancer
Wnt/β-catenin-in-1 (compounds 17) is a *Wnt/β-catenin* signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .

HY-155391

hCA/Wnt/β-catenin-IN-1	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits *Wnt/β-catenin* signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

HY-P1416

Foxy-5 4 Publications Verification	Wnt	Cancer
Foxy-5, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-168593

Wnt/β-catenin-IN-5	β-catenin PROTACs Histone Demethylase	Cancer
Wnt/β-catenin-IN-5 (Compound 4) is an inhibitor of the *Wnt/β-catenin* signaling pathway. Wnt/β-catenin-IN-5 eliminates colorectal cancer stem cells and inhibits tumor growth by suppressing the *Wnt* signaling pathway. PROTACs Wnt/β-catenin-IN-5, which is also a PROTAC based on IOX1, effectively induces the degradation of KDM3A and KDM3B (Target protein ligand (Pink): HY-12304; linker (Black): HY-22335; Conjugate of E3 ligase ligand and linker: HY-112599; E3 ligase (Blue): HY-41547) .

HY-10593

IQ 1	Wnt	Others
IQ 1 is a *Wnt/β-catenin/CBP* signalling sustainer. IQ 1 maintains long-term expansion of *Wnt/β-catenin*-driven mouse embryonic stem cells (ESCs) and prevents spontaneous differentiation by enhancing *β-catenin/CBP*-mediated transcription and preventing conversion to *β-catenin/p300*-mediated transcription. IQ-1 regulates *Wnt* signalling by interacting with PR72/130. IQ 1 can be used in study of ESCs expansion .

HY-12238

IWR-1 35+ Cited Publications endo-IWR 1; IWR-1-endo	Organoid Wnt	Cancer
IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway.

HY-P1416A

Foxy-5 TFA 4 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-162970

XD23	Others	Cancer
XD23 is a potent osteosarcoma inhibitor that works by downregulating DKK1 and activating the WNT/β-catenin signaling pathway.

HY-137454

Teplinovivint	Wnt β-catenin	Inflammation/Immunology
Teplinovivint is a potent *wnt/β-catenin* signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research .

HY-16910

WIKI4 2 Publications Verification	PARP β-catenin	Cancer
WIKI4 is a potent tankyrase inhibitor with an IC₅₀ of 26 nM for TNKS2. WIKI4 potently inhibits *Wnt/β-catenin* signaling and that its half-maximal response dose is 75 nM. WIKI4 mediates its effects on *Wnt/β-catenin* signaling by inhibiting the enzymatic activity of TNKS2 . WIKI4 is cytotoxic to SCLC cells with an IC₅₀ value of 0.02 μM .

HY-111460

15-Oxospiramilactone NC 043	Wnt	Cancer
15-Oxospiramilactone is a diterpene derivative. 15-Oxospiramilactone can inhibit *Wnt/β-catenin* signaling and tumorigenesis of colon cancer cells .

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based *Wnt/β-catenin* signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .

HY-P4858

C-Peptide 1 (rat)	GSK-3	Cancer
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .

HY-153214

YW2036	Wnt β-catenin	Cancer
YW2036 (compound 2a) is a potent Wnt/β-Catenin signaling pathway inhibitor with an IC₅₀ value of 637 nM. YW2036 can be used in research of cancer .

HY-N0020

Echinacoside 5+ Cited Publications	Wnt Reactive Oxygen Species	Neurological Disease
Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits **Wnt/β-catenin signaling*. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal* pathways. Antiosteoporotic activity .

HY-N0432

Astragaloside I Astrasieversianin IV; Cyclosieversioside B	Wnt β-catenin	Metabolic Disease
Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through the *Wnt/β-catenin* signaling pathway .

HY-108441

CCT031374 hydrobromide	β-catenin	Cancer
CCT 031374 hydrobromid is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. CCT031374 inhibits TCF-dependent transcription of genes of Wnt signaling pathway. CCT 031374 has antitumor activity .

HY-P10392AF

fStAx-35R TFA	β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits *Wnt/β-catenin* signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-N2785

Desmethylicaritin	Wnt	Metabolic Disease
Desmethylicaritin is a phytoestrogenic molecule, has inducible effect on directional differentiation of embryonic stem cells into cardiomyocytes. Desmethylicaritin also suppresses adipogenesis via Wnt/β-catenin signaling pathway .

HY-117233

UU-T02 1 Publications Verification	β-catenin Wnt	Metabolic Disease Cancer
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction *(β-catenin/Tcf PPI)* with a K_i of 1.36 μM . UU-T02 inhibits canonical *Wnt* signaling and the growth of colorectal cancer cells .

HY-17439

Salinomycin sodium salt 30+ Cited Publications Salinomycin sodium; Sodium salinomycin	Wnt β-catenin Bacterial Autophagy Apoptosis Antibiotic Parasite	Cancer
Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of *Wnt/β-catenin* signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells .

HY-164547

WHN-88	Porcupine Wnt β-catenin	Cancer
WHN-88 is a Porcupine (PORCN) inhibitor. WHN-88 can eliminate the palmitoylation of *Wnt* ligands, preventing their secretion and subsequent *Wnt/β-catenin* signaling. WHN-88 can inhibit cancer cell stemness and suppress the occurrence and development of breast tumors in MMTV-Wnt1 transgenic mice .

HY-B0012

Pamidronic acid 1 Publications Verification	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of *Wnt* and *β-catenin*, and is applicable for research on osteoporosis and osteosarcoma .

HY-B0012B

Pamidronic acid sodium	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of *Wnt* and *β-catenin*, and is applicable for research on osteoporosis and osteosarcoma .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1,666 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,666 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P5819

xStAx-VHLL	Wnt PROTACs β-catenin	Cancer
xStAx-VHLL is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of *β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin* signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin Wnt	Cancer
xStAx-VHLL TFA is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of *β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin* signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P1416

Foxy-5 4 Publications Verification	Wnt	Cancer
Foxy-5, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1416A

Foxy-5 TFA 4 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P4858

C-Peptide 1 (rat)	GSK-3	Cancer
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .

HY-P10392AF

fStAx-35R TFA	β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits *Wnt/β-catenin* signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P2272A

NLS-StAx-h TFA 1 Publications Verification	Wnt β-catenin	Cancer
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide *Wnt* signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h TFA efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h TFA shows anti-proliferation of cancer cells .

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P2272

NLS-StAx-h	Wnt β-catenin	Cancer
NLS-StAx-h is a selective, cell permeable, stapled peptide *Wnt* signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .

HY-P1454

Fz7-21 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .

HY-P1454A

Fz7-21 TFA 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2 TFA	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks